00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
15:00 , Oct 20, 2017 |  BC Week In Review  |  Financial News

Resverlogix raises C$87M in private placement

On Oct. 13, Resverlogix Corp. (TSX:RVX) said Chinese API distributor Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) invested C$87 million ($69.7 million) in a private placement through the issue of 60.4 million units at C$1.44. Each...
21:59 , Oct 13, 2017 |  BC Extra  |  Financial News

Shenzhen Hepalink triples stake in Resverlogix

Resverlogix Corp. (TSX:RVX) said Chinese API distributor Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) invested C$87 ($69.7 million) in a private placement through the issue of 60.4 million units at C$1.44. Each unit consists of a...
19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
20:16 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

DSMB recommends fourth continuation of Phase III BETonMACE trial of apabetalone

Resverlogix Corp. (TSX:RVX) said an independent DSMB recommended for the fourth time continuation of the double-blind, placebo-controlled, international Phase III BETonMACE trial evaluating twice-daily 100 mg apabetalone (RVX000222, RVX-208) with high-dose statin therapy in patients...
19:11 , Jun 23, 2017 |  BC Week In Review  |  Financial News

Resverlogix completes private placement and overnight marketed equity offering

Resverlogix Corp. (TSX:RVX) raised C$9.9 million ($7.5 million) through the sale of 5.5 million units at C$1.80 in a two-part offering which closed on June 20. Resverlogix sold 3 million units to existing investors Eastern...
20:54 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

Apabetalone: Ph III ongoing

Resverlogix said an independent DSMB recommended for the third time continuation of the double-blind, placebo-controlled, international Phase III BETonMACE trial evaluating 100 mg apabetalone twice daily with high-dose statin therapy. The company said the DSMB...